GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Inventories, Other

Albireo Pharma (FRA:BDQM) Inventories, Other : €0.00 Mil (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Albireo Pharma's other inventories for the quarter that ended in Sep. 2022 was €0.00 Mil.

Albireo Pharma's quarterly other inventories increased from Mar. 2022 (€0.00 Mil) to Jun. 2022 (€0.00 Mil) but then declined from Jun. 2022 (€0.00 Mil) to Sep. 2022 (€0.00 Mil).


Albireo Pharma Inventories, Other Historical Data

The historical data trend for Albireo Pharma's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Inventories, Other Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Albireo Pharma Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines